|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.3 USD | +0.11% |
|
-4.42% | -8.47% |
| Apr. 17 | Sector Update: Health Care Stocks Mixed Wednesday Afternoon | MT |
| Apr. 17 | Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise | MT |
Celldex Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 4.13 million compared to USD 1.61 million a year ago. Net loss was USD 43.31 million compared to USD 26.49 million a year ago.
Basic loss per share from continuing operations was USD 0.83 compared to USD 0.56 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.47% | 2.39B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
CELLDEX THERAPEUTICS, INC. 
